Sudeep Pharma Q1 FY27 Consolidated Net Profit Rs. 4,058.69 Lakhs
RESULTS
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 04 Aug 2026, 06:02 PM IST · BSE ID: fbb74c35-1fa5-4bba-8b85-272272d5fe7c
View Original BSE Filing (PDF)
💡
In Simple Terms
Sudeep Pharma announced its first quarter financial results, showing Rs. 15,827.05 Lakhs in revenue and Rs. 4,058.69 Lakhs net profit.
🤖 AI Summary
- Board approved unaudited consolidated financial results for the first quarter ended June 30, 2026.
- Consolidated revenue from operations for Q1 FY27 stood at Rs. 15,827.05 Lakhs.
- Consolidated net profit for the period was Rs. 4,058.69 Lakhs for the quarter ended June 30, 2026.
- Sudeep Pharma listed its equity shares on NSE and BSE on November 28, 2025.
- Unutilised net IPO proceeds of Rs. 7,545.63 Lakhs are held as term deposits as of June 30, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Consolidated Revenue from Operations
Rs. 15,827.05 Lakhs
26.70%
Consolidated Total Income
Rs. 16,371.59 Lakhs
25.86%
Consolidated Profit for the period (Net Profit)
Rs. 4,058.69 Lakhs
29.80%
Basic Earnings per Equity Share
Rs. 3.59
26.41%
Unutilised Net IPO Proceeds
Rs. 7,545.63 Lakhs
🏢 How This Affects the Company
The company's Pharmaceutical, food and nutrition segment generated Rs. 10,841.37 Lakhs in external revenue, while Speciality ingredients contributed Rs. 4,985.68 Lakhs in Q1 FY27.
Consolidated total income was Rs. 16,371.59 Lakhs, leading to a profit before tax of Rs. 5,429.26 Lakhs and a net profit of Rs. 4,058.69 Lakhs for Q1 FY27.
Unutilised IPO proceeds of Rs. 7,545.63 Lakhs designated for capital expenditure on machinery for the Nandesari Facility remain as term deposits.
The Limited Review Report notes that financial results of two subsidiaries, reflecting Rs. 1,139.55 Lakhs total revenues and Rs. 49.12 Lakhs total net loss, were not reviewed.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, with the consolidated net profit attributable to owners of the Group at Rs. 4,055.00 Lakhs for Q1 FY27.
🔍
Management Signal
Management approved the Q1 FY27 financial results and continues to hold significant unutilised IPO proceeds in term deposits, indicating a measured approach to capital deployment.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 financial results — assess sustained revenue and profit growth.
Updates on IPO proceeds utilisation for Nandesari Facility machinery procurement.
Further details on the financial performance of unreviewed subsidiaries.
MEDIUM RISK
The non-review of two subsidiaries' financial results introduces a degree of uncertainty in the consolidated figures.
💡 Investor Takeaway
Sudeep Pharma reported Q1 FY27 consolidated revenue from operations of Rs. 15,827.05 Lakhs, an increase of 26.70% from Rs. 12,491.75 Lakhs in Q1 FY26. Consolidated net profit reached Rs. 4,058.69 Lakhs, up 29.80% YoY from Rs. 3,126.92 Lakhs.
⚖️ Strengths & Concerns
✅ Positives
- Consolidated revenue from operations increased to Rs. 15,827.05 Lakhs in Q1 FY27 from Rs. 12,491.75 Lakhs in Q1 FY26, showing 26.70% YoY growth.
- Consolidated profit after tax grew to Rs. 4,058.69 Lakhs in Q1 FY27 from Rs. 3,126.92 Lakhs in Q1 FY26, a 29.80% YoY increase.
⚠️ Concerns
- Two subsidiaries, contributing Rs. 1,139.55 Lakhs in total revenues and Rs. 49.12 Lakhs in net loss, had their financial results unreviewed in the consolidated statement.
- As of June 30, 2026, Rs. 7,545.63 Lakhs of IPO net proceeds for capital expenditure are unutilised and held as term deposits.
📅 Company Track Record
Sudeep Pharma Limited's equity shares were listed on the National Stock Exchange of India Limited (NSE) and Bombay Stock Exchange Limited (BSE) on November 28, 2025. The company raised net IPO proceeds of Rs. 8,833.59 Lakhs.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Sudeep Pharma's consolidated net profit for Q1 FY27?
Sudeep Pharma's consolidated net profit for the quarter ended June 30, 2026, was Rs. 4,058.69 Lakhs.
What was Sudeep Pharma's consolidated revenue from operations for Q1 FY27?
The consolidated revenue from operations for Sudeep Pharma for the quarter ended June 30, 2026, was Rs. 15,827.05 Lakhs.
When were Sudeep Pharma's equity shares listed?
Sudeep Pharma's equity shares were listed on the National Stock Exchange of India Limited (NSE) and Bombay Stock Exchange Limited (BSE) on November 28, 2025.
What amount of IPO proceeds remains unutilised as of June 30, 2026?
As of June 30, 2026, Rs. 7,545.63 Lakhs of the net IPO proceeds remain unutilised and are held as term deposits.
What were the external revenues for Sudeep Pharma's segments in Q1 FY27?
For Q1 FY27, Pharmaceutical, food and nutrition segment recorded Rs. 10,841.37 Lakhs in external revenues, and Speciality ingredients segment recorded Rs. 4,985.68 Lakhs.
Questions based on this BSE filing only. For information purposes.